David M Nathan1. Show Affiliations » 1. Diabetes Center, Massachusetts General Hospital, Boston, USA.
Abstract
Entities: Disease
Mesh： See more » Adenosine Deaminase InhibitorsClinical Trials as TopicDiabetes Mellitus, Type 2/drug therapyDipeptidyl Peptidase 4Dipeptidyl-Peptidase IV InhibitorsDrug ApprovalGlucagon-Like Peptide 1/drug effectsGlucagon-Like Peptide 1/metabolismGlycoproteins/antagonists & inhibitorsHistory, 20th CenturyHistory, 21st CenturyHumansHypoglycemic Agents/historyHypoglycemic Agents/therapeutic usePeptide Fragments/drug effectsPeptide Fragments/metabolismPyrazines/therapeutic useSitagliptin PhosphateTriazoles/therapeutic useUnited StatesUnited States Food and Drug Administration
Substances： See more » Adenosine Deaminase InhibitorsDipeptidyl-Peptidase IV InhibitorsGlycoproteinsHypoglycemic AgentsPeptide FragmentsPyrazinesTriazolesGlucagon-Like Peptide 1DPP4 protein, humanDipeptidyl Peptidase 4glucagon-like peptide 1 (7-37)Sitagliptin Phosphate
Year: 2007 PMID： 17267901 DOI： 10.1056/NEJMp068294
Source DB: PubMed Journal: N Engl J Med ISSN： 0028-4793 Impact factor: 91.245